Kaken Pharmaceutical Future Growth
Future criteria checks 0/6
Kaken Pharmaceutical's revenue and earnings are forecast to decline at 6.1% and 30.7% per annum respectively. EPS is expected to decline by 30.8% per annum. Return on equity is forecast to be 1.4% in 3 years.
Key information
-30.7%
Earnings growth rate
-30.8%
EPS growth rate
Pharmaceuticals earnings growth | 12.6% |
Revenue growth rate | -6.1% |
Future return on equity | 1.4% |
Analyst coverage | Low |
Last updated | 07 Feb 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 58,300 | 920 | 3,222 | N/A | 1 |
3/31/2026 | 66,600 | 5,280 | 6,322 | N/A | 1 |
3/31/2025 | 70,200 | 6,620 | 7,622 | N/A | 1 |
3/31/2024 | 72,700 | 7,620 | 8,023 | N/A | 1 |
12/31/2023 | 72,096 | 2,966 | N/A | N/A | N/A |
9/30/2023 | 72,336 | 3,544 | 714 | 2,581 | N/A |
6/30/2023 | 72,937 | 5,043 | N/A | N/A | N/A |
3/31/2023 | 72,984 | 5,440 | 7,047 | 9,253 | N/A |
12/31/2022 | 73,899 | 8,452 | N/A | N/A | N/A |
9/30/2022 | 75,265 | 8,792 | 11,478 | 14,329 | N/A |
6/30/2022 | 75,778 | 9,094 | N/A | N/A | N/A |
3/31/2022 | 76,034 | 9,549 | 10,079 | 13,336 | N/A |
12/31/2021 | 75,605 | 12,717 | N/A | N/A | N/A |
9/30/2021 | 75,778 | 12,900 | 10,134 | 13,123 | N/A |
6/30/2021 | 75,362 | 12,947 | N/A | N/A | N/A |
3/31/2021 | 74,979 | 13,405 | 12,094 | 14,380 | N/A |
12/31/2020 | 76,136 | 14,750 | N/A | N/A | N/A |
9/30/2020 | 80,851 | 17,049 | 16,658 | 18,502 | N/A |
6/30/2020 | 84,967 | 18,364 | N/A | N/A | N/A |
3/31/2020 | 89,232 | 19,370 | 25,266 | 27,468 | N/A |
12/31/2019 | 91,759 | 19,082 | N/A | N/A | N/A |
9/30/2019 | 91,814 | 18,482 | 27,065 | 29,746 | N/A |
6/30/2019 | 92,365 | 18,566 | N/A | N/A | N/A |
3/31/2019 | 94,165 | 17,775 | 19,001 | 21,129 | N/A |
12/31/2018 | 94,123 | 16,431 | N/A | N/A | N/A |
9/30/2018 | 96,091 | 17,015 | 15,607 | 17,657 | N/A |
6/30/2018 | 97,598 | 17,615 | N/A | N/A | N/A |
3/31/2018 | 98,430 | 19,043 | 19,815 | 21,703 | N/A |
12/31/2017 | 99,405 | 20,893 | N/A | N/A | N/A |
9/30/2017 | 99,160 | 21,439 | N/A | 20,714 | N/A |
6/30/2017 | 100,218 | 21,684 | N/A | N/A | N/A |
3/31/2017 | 101,479 | 22,017 | N/A | 15,327 | N/A |
12/31/2016 | 103,264 | 18,992 | N/A | N/A | N/A |
9/30/2016 | 106,936 | 20,106 | N/A | 22,215 | N/A |
6/30/2016 | 108,325 | 20,639 | N/A | N/A | N/A |
3/31/2016 | 109,730 | 21,143 | N/A | 27,067 | N/A |
12/31/2015 | 108,165 | 22,651 | N/A | N/A | N/A |
9/30/2015 | 104,630 | 18,966 | N/A | 22,113 | N/A |
6/30/2015 | 100,058 | 15,792 | N/A | N/A | N/A |
3/31/2015 | 93,889 | 12,122 | N/A | 14,737 | N/A |
12/31/2014 | 93,083 | 11,909 | N/A | N/A | N/A |
9/30/2014 | 89,466 | 10,776 | N/A | 10,586 | N/A |
6/30/2014 | 89,140 | 10,158 | N/A | N/A | N/A |
3/31/2014 | 88,946 | 9,735 | N/A | 13,663 | N/A |
12/31/2013 | 87,267 | 9,042 | N/A | N/A | N/A |
9/30/2013 | 87,243 | 8,973 | N/A | 12,340 | N/A |
6/30/2013 | 87,543 | 9,096 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4521's earnings are forecast to decline over the next 3 years (-30.7% per year).
Earnings vs Market: 4521's earnings are forecast to decline over the next 3 years (-30.7% per year).
High Growth Earnings: 4521's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 4521's revenue is expected to decline over the next 3 years (-6.1% per year).
High Growth Revenue: 4521's revenue is forecast to decline over the next 3 years (-6.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4521's Return on Equity is forecast to be low in 3 years time (1.4%).